-+ 0.00%
-+ 0.00%
-+ 0.00%

Iambic Receives Clearance for Phase 1/2 Trial of Cancer Drug IAM217

PUBT·11/18/2026 13:04:39
Listen to the news
Iambic Receives Clearance for Phase 1/2 Trial of Cancer Drug IAM217
  • Iambic Therapeutics will present preclinical results for IAM-C1 and IAM217 at the EORTC-NCI-AACR Symposium in Barcelona on November 19-20, 2026.
  • IAM-C1 suppressed tumor growth in treatment-resistant breast cancer models, with smaller neutrophil reductions than combined selective CDK2 and CDK4 inhibition.
  • Brain-penetrant IAM217 produced substantial tumor regressions across several cancer models, including a breast cancer brain metastasis model.
  • IAM217 has received a Safe-to-Proceed Letter for a Phase 1/2 trial.
  • An investigational new drug application for IAM-C1 is expected in the fourth quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iambic Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180800PRIMZONEFULLFEED9880180) on November 18, 2026, and is solely responsible for the information contained therein.